MarketerRedHill Biopharma, Ltd.
MOVANTIK® (naloxegol) is a peripherally acting μ-opioid receptor antagonist that was licensed by Nektar to AstraZeneca where it was developed for the treatment of opioid-induced constipation. MOVANTIK was approved in 2014 in adult patients with chronic, non-cancer pain and is now marketed by RedHill Biopharma.
HCR purchased the royalty interests on worldwide net sales of ADYNOVATE and MOVANTIK from Nektar Therapeutics. Nektar monetized these non-strategic royalty interests in order to further fund development of its strategic pipeline.
Note: This transaction also appears in the Corporate Financing section under NEKTAR.